Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists

Kasper Bø Hansen; Praseeda Mullasseril; Sara Dawit; Natalie L Kurtkaya; Hongjie Yuan; Katie M Vance; Anna G Orr; Trine Kvist; Kevin K Ogden; Phuong Le; Kimberly M Vellano; Iestyn Lewis; Serdar Kurtkaya; Yuhong Du; Min Qui; T J Murphy; James P Snyder; Hans Bräuner-Osborne; Stephen F Traynelis

doi:10.1124/jpet.110.166256

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists

Kasper Bø Hansen, Praseeda Mullasseril, Sara Dawit, Natalie L Kurtkaya, Hongjie Yuan, Katie M Vance, Anna G Orr, Trine Kvist, Kevin K Ogden, Phuong Le, Kimberly M Vellano, Iestyn Lewis, Serdar Kurtkaya, Yuhong Du, Min Qui, T J Murphy, James P Snyder, Hans Bräuner-Osborne, Stephen F Traynelis

33 Citations (Scopus)

Abstract

N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca(2+)-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.

Original language	English
Journal	Journal of Pharmacology and Experimental Therapeutics
Volume	333
Issue number	3
Pages (from-to)	650-662
ISSN	0022-3565
DOIs	https://doi.org/10.1124/jpet.110.166256
Publication status	Published - Jun 2010

Keywords

Former Faculty of Pharmaceutical Sciences

Access to Document

10.1124/jpet.110.166256

Cite this

Hansen, K. B., Mullasseril, P., Dawit, S., Kurtkaya, N. L., Yuan, H., Vance, K. M., Orr, A. G., Kvist, T., Ogden, K. K., Le, P., Vellano, K. M., Lewis, I., Kurtkaya, S., Du, Y., Qui, M., Murphy, T. J., Snyder, J. P., Bräuner-Osborne, H., & Traynelis, S. F. (2010). Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. Journal of Pharmacology and Experimental Therapeutics, 333(3), 650-662. https://doi.org/10.1124/jpet.110.166256

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. / Hansen, Kasper Bø; Mullasseril, Praseeda; Dawit, Sara et al.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 333, No. 3, 06.2010, p. 650-662.

Research output: Contribution to journal › Journal article › Research › peer-review

Hansen, KB, Mullasseril, P, Dawit, S, Kurtkaya, NL, Yuan, H, Vance, KM, Orr, AG, Kvist, T, Ogden, KK, Le, P, Vellano, KM, Lewis, I, Kurtkaya, S, Du, Y, Qui, M, Murphy, TJ, Snyder, JP, Bräuner-Osborne, H & Traynelis, SF 2010, 'Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists', Journal of Pharmacology and Experimental Therapeutics, vol. 333, no. 3, pp. 650-662. https://doi.org/10.1124/jpet.110.166256

Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. Journal of Pharmacology and Experimental Therapeutics. 2010 Jun;333(3):650-662. doi: 10.1124/jpet.110.166256

@article{918b6010b73e11df825b000ea68e967b,

title = "Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists",

abstract = "N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca(2+)-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.",

keywords = "Former Faculty of Pharmaceutical Sciences",

author = "Hansen, {Kasper B{\o}} and Praseeda Mullasseril and Sara Dawit and Kurtkaya, {Natalie L} and Hongjie Yuan and Vance, {Katie M} and Orr, {Anna G} and Trine Kvist and Ogden, {Kevin K} and Phuong Le and Vellano, {Kimberly M} and Iestyn Lewis and Serdar Kurtkaya and Yuhong Du and Min Qui and Murphy, {T J} and Snyder, {James P} and Hans Br{\"a}uner-Osborne and Traynelis, {Stephen F}",

note = "Keywords: Aniline Compounds; Animals; Cell Line; Cricetinae; Drug Evaluation, Preclinical; Electrophysiology; Excitatory Amino Acid Antagonists; Fluorescent Dyes; Histamine H3 Antagonists; Humans; Imidazoles; Isothiuronium; Microscopy, Fluorescence; Oocytes; Patch-Clamp Techniques; Piperidines; Radioligand Assay; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Thiourea; Xanthenes; Xenopus laevis",

year = "2010",

month = jun,

doi = "10.1124/jpet.110.166256",

language = "English",

volume = "333",

pages = "650--662",

journal = "Journal of Pharmacology and Experimental Therapeutics",

issn = "0022-3565",

publisher = "American Society for Pharmacology and Experimental Therapeutics",

number = "3",

}

TY - JOUR

T1 - Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists

AU - Hansen, Kasper Bø

AU - Mullasseril, Praseeda

AU - Dawit, Sara

AU - Kurtkaya, Natalie L

AU - Yuan, Hongjie

AU - Vance, Katie M

AU - Orr, Anna G

AU - Kvist, Trine

AU - Ogden, Kevin K

AU - Le, Phuong

AU - Vellano, Kimberly M

AU - Lewis, Iestyn

AU - Kurtkaya, Serdar

AU - Du, Yuhong

AU - Qui, Min

AU - Murphy, T J

AU - Snyder, James P

AU - Bräuner-Osborne, Hans

AU - Traynelis, Stephen F

N1 - Keywords: Aniline Compounds; Animals; Cell Line; Cricetinae; Drug Evaluation, Preclinical; Electrophysiology; Excitatory Amino Acid Antagonists; Fluorescent Dyes; Histamine H3 Antagonists; Humans; Imidazoles; Isothiuronium; Microscopy, Fluorescence; Oocytes; Patch-Clamp Techniques; Piperidines; Radioligand Assay; Receptors, N-Methyl-D-Aspartate; Structure-Activity Relationship; Thiourea; Xanthenes; Xenopus laevis

PY - 2010/6

Y1 - 2010/6

N2 - N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca(2+)-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.

AB - N-Methyl-D-aspartate (NMDA) receptors are ligand-gated ion channels that mediate a slow, Ca(2+)-permeable component of excitatory synaptic transmission in the central nervous system and play a pivotal role in synaptic plasticity, neuronal development, and several neurological diseases. We describe a fluorescence-based assay that measures NMDA receptor-mediated changes in intracellular calcium in a BHK-21 cell line stably expressing NMDA receptor NR2D with NR1 under the control of a tetracycline-inducible promoter (Tet-On). The assay selectively identifies allosteric modulators by using supramaximal concentrations of glutamate and glycine to minimize detection of competitive antagonists. The assay is validated by successfully identifying known noncompetitive, but not competitive NMDA receptor antagonists among 1800 screened compounds from two small focused libraries, including the commercially available library of pharmacologically active compounds. Hits from the primary screen are validated through a secondary screen that used two-electrode voltage-clamp recordings on recombinant NMDA receptors expressed in Xenopus laevis oocytes. This strategy identified several novel modulators of NMDA receptor function, including the histamine H3 receptor antagonists clobenpropit and iodophenpropit, as well as the vanilloid receptor transient receptor potential cation channel, subfamily V, member 1 (TRPV1) antagonist capsazepine. These compounds are noncompetitive antagonists and the histamine H3 receptor ligand showed submicromolar potency at NR1/NR2B NMDA receptors, which raises the possibility that compounds can be developed that act with high potency on both glutamate and histamine receptor systems simultaneously. Furthermore, it is possible that some actions attributed to histamine H3 receptor inhibition in vivo may also involve NMDA receptor antagonism.

KW - Former Faculty of Pharmaceutical Sciences

U2 - 10.1124/jpet.110.166256

DO - 10.1124/jpet.110.166256

M3 - Journal article

C2 - 20197375

SN - 0022-3565

VL - 333

SP - 650

EP - 662

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

IS - 3

ER -

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists

Abstract

Keywords

Access to Document

Fingerprint

Cite this